This afternoon we watched Henry Schein drop -1.8% to a price of $64.93 per share. The large-cap Medical Specialities company is now trading -20.47% below its average target price of $81.64. Analysts have set target prices ranging from $69.0 to $94.0 per share for Henry Schein, and have given the stock an average rating of hold.
The stock has an average amount of shares sold short at 2.0%, and a short ratio of 3.04. Since 1.04% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.5% of Henry Schein's shares being owned by this investor type.
Institutions Invested in Henry Schein
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 12% | 15,199,278 | $986,889,125 |
| 2023-06-30 | Generation Investment Management LLP | 9% | 12,269,664 | $796,669,287 |
| 2023-06-30 | Blackrock Inc. | 8% | 9,940,562 | $645,440,693 |
| 2023-06-30 | State Street Corporation | 5% | 6,735,287 | $437,322,186 |
| 2023-06-30 | Invesco Ltd. | 4% | 5,328,239 | $345,962,559 |
| 2023-06-30 | JP Morgan Chase & Company | 4% | 4,712,799 | $306,002,040 |
| 2023-06-30 | American Century Companies, Inc. | 3% | 4,396,439 | $285,460,785 |
| 2023-09-30 | Perpetual Ltd. | 3% | 4,279,046 | $277,838,458 |
| 2023-06-30 | Longview Partners (Guernsey) LTD | 2% | 3,246,157 | $210,772,975 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 3,194,907 | $207,445,312 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Henry Schein.
